Meridian Bioscience Inc. (VIVO) Social Stream
Featured Post From StockTwits About VIVO
$VIVO Only positive is that on their ER call a few weeks ago they raised guidance....YouOnlyLiveTwice, published June 2, 2021
Also Value Line said BUY
But then why did this trade such high volume today?
All because of that POS Navelloer?
What Else are VIVO Traders Talking About?
Other Notable StockTweets About VIVO
$VIVO MACD crossover occurred today, 5/18 (bullish), as $VIVO continues its bounce off the lower Bollinger from last week. As I have said-the company has a good capital structure, strong liquidity, 28% projected sales growth with 27% Net Margin (Industry -8%) and 32% ROE (Industry -1%). Q1 earnings were favorable, along with the 2021 outlook full year. Net Revenue and EPS (2021FY) remain inline with estimates, even with excluding the Revogene SARS-CoV-2 assay from the financials. Analysts have maintained $VIVO a Buy recommendation with an Avg 12mos PT of $32 (currently trading at $19). The stock is now trading at a P/E of 11, P/S of 2.5. This is an amazing growth and value play in the biotech space, oversold considerably from Q1. My other favorite biotech plays currently are: $ONCY, $OBSV, $VTGN, $SENSBinaryLogic, published May 18, 2021
$VIVO I took a position on Meridian yesterday on the fall below $19, because I see strong value/growth at this price. $VIVO bounced off the lower Bollinger today on modest volume, MACD remains bearish and RSI 31 (oversold). $VIVO has a good capital structure, strong liquidity, 28% projected sales growth with 27% Net Margin (Industry -8%) and 32% ROE (Industry -1%). The stock is now trading at a P/E of 11, P/S of 2.5. This is an amazing growth and value play in the biotech space, oversold considerably from Q1. I know about the issues re: FDA withdraw on the COVID diagnostics, and I am still upset with the executive team on the way they handled the announcement, liquidating stock just ahead of the formal announcement on FDA COVID delay. That said-it is difficult for me to find a better value/growth play in the biotech space, and I plan to give the company another chance. Strong historical support $15-18, and Q2 earnings were excellent, so there is limited downside risk here IMOBinaryLogic, published May 12, 2021